Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Expected to Announce Quarterly Sales of $8.31 Million

Wall Street analysts expect Alpine Immune Sciences, Inc. (NASDAQ:ALPNGet Rating) to report $8.31 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Alpine Immune Sciences’ earnings. The lowest sales estimate is $4.60 million and the highest is $15.33 million. Alpine Immune Sciences reported sales of $7.19 million during the same quarter last year, which indicates a positive year-over-year growth rate of 15.6%. The firm is expected to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Alpine Immune Sciences will report full-year sales of $65.98 million for the current fiscal year, with estimates ranging from $37.00 million to $102.00 million. For the next fiscal year, analysts forecast that the company will report sales of $40.07 million, with estimates ranging from $32.00 million to $45.90 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPNGet Rating) last issued its quarterly earnings data on Thursday, May 12th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.06). Alpine Immune Sciences had a negative net margin of 139.41% and a negative return on equity of 46.87%.

ALPN has been the topic of several research analyst reports. Zacks Investment Research cut Alpine Immune Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, March 22nd. Wedbush restated an “outperform” rating and set a $22.00 target price on shares of Alpine Immune Sciences in a report on Tuesday, May 17th. Oppenheimer decreased their target price on Alpine Immune Sciences from $19.00 to $17.00 in a report on Monday, March 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $21.00 price target on shares of Alpine Immune Sciences in a report on Friday, May 13th.

Institutional investors have recently bought and sold shares of the stock. Barclays PLC boosted its holdings in Alpine Immune Sciences by 223.1% in the third quarter. Barclays PLC now owns 4,747 shares of the biotechnology company’s stock valued at $51,000 after acquiring an additional 3,278 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Alpine Immune Sciences by 1.3% in the third quarter. Geode Capital Management LLC now owns 194,021 shares of the biotechnology company’s stock valued at $2,070,000 after acquiring an additional 2,483 shares during the last quarter. BlackRock Inc. boosted its holdings in Alpine Immune Sciences by 0.7% in the third quarter. BlackRock Inc. now owns 547,782 shares of the biotechnology company’s stock valued at $5,844,000 after acquiring an additional 3,627 shares during the last quarter. Two Sigma Investments LP lifted its stake in Alpine Immune Sciences by 131.9% in the third quarter. Two Sigma Investments LP now owns 39,218 shares of the biotechnology company’s stock valued at $418,000 after buying an additional 22,304 shares during the period. Finally, Frazier Management LLC lifted its stake in Alpine Immune Sciences by 0.7% in the fourth quarter. Frazier Management LLC now owns 1,784,913 shares of the biotechnology company’s stock valued at $24,721,000 after buying an additional 13,069 shares during the period. Institutional investors and hedge funds own 77.00% of the company’s stock.

Shares of NASDAQ ALPN opened at $8.25 on Thursday. The firm’s 50-day simple moving average is $8.59 and its 200 day simple moving average is $9.83. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.02. The stock has a market cap of $250.22 million, a P/E ratio of -4.63 and a beta of 1.74. Alpine Immune Sciences has a fifty-two week low of $6.00 and a fifty-two week high of $14.40.

About Alpine Immune Sciences (Get Rating)

Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.

Featured Stories

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.